Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374692 · ClinicalTrials.gov registry record · NA
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
A NA study of Brain Cancer and Gliomas, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07374692 is a NA study of Brain Cancer and Gliomas that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants, below the 506-participant average among 47 other Brain Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07374692, a NA study of Brain Cancer and Gliomas, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgically removed tumor tissue react to different drugs. The study team wants to see if SmartMatch can complete the analysis and generate a report within 21 days from the time of the surgery. Objective: To better understand CNS tumors so doctors can find better ways to treat them in the future. Eligibility: People aged 15 years and older with recurrent CNS tumors. Patient must already be scheduled for a surgery for the tumor at the NIH. Design: The study team will collect a small amount of tumor samples during the planned surgery. They may also use tumor samples from previous procedures. No new or additional procedures will be done for the purpose of this study. The tumor samples will be sent to a lab for SmartMatch analysis. Once completed, the results will be shared with the patient and his/her local doctor. Together they can decide whether to incorporate the results into the treatment plan. It is important to know that the results may or may not be helpful. There will only be one blood test for research. Blood and tissue samples collected may be used for additional analysis. Tumor tissue may be used to grow additional samples for further study. Participants will receive a pathology diagnosis and mutation profile generated by pathologists who specialize in CNS tumors. The study team will seek updates on participant's health approximately every 6 months for 3 years. Tumor samples may also be collected from any additional surgery done at NIH during this time.
Conditions Studied
Interventions
- OTHER Tumor sample collection
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02-04 |
| Est. Completion | 2030-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07374692
The ClinicalTrials.gov registry entry for NCT07374692 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 47 other Brain Cancer trials with a reported enrollment target (84% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Brain Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tumor sample collection is the first listed.
NCT07374692 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07374692 about?
NCT07374692 is a clinical study titled "Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors". Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgic...
What is the current status of trial NCT07374692?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2026-02-04. Estimated completion is 2030-12-30.
What conditions does trial NCT07374692 study?
This clinical trial studies the following conditions: Brain Cancer, Gliomas, Recurrent CNS Tumors, IDH-wildtype Gliomas, IDH-mutant Gliomas.
What interventions are being tested in trial NCT07374692?
The interventions under investigation include: Tumor sample collection (OTHER).
Who is sponsoring clinical trial NCT07374692?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07374692 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
-
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
RECRUITING · NA
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
RECRUITING · NA
-
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
ACTIVE NOT RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.